Cliff notes: drug revenues barely kept pace last year, as other indicators like numbers of protected brands and reps have decreased, amid the overall trend of industry consolidation. With more products set to take the plunge over the patent cliff, analysts say margins are due to be tight for the foreseeable future. Marc Iskowitz and Matthew Arnold report

MM&M takes a look at the top 20 drug manufacturers and breaks down the sales data by company, prescription drugs and therapeutic class. We also track total promotional spend, professional [...]